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Anticoagulation monitoring by an anticoagulation
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Background:Vitamin K antagonists (VKAs) are the mainstay of long-term anticoagulation but require careful monitoring
for effectiveness and safety. Physicians manage anticoagulation for most patients, although anticoagulation services are
becoming increasingly popular. A new anticoagulation service (AS) run by nurses and overseen by a physician was
established and its effectiveness vs usual physician care was independently assessed using costs of emergency department
(ED) visits and hospitalizations resulting from failure or complication of anticoagulation. We report the results of this
independent analysis of anticoagulation monitoring of patients treated with VKAs.
Methods: The AS-treated patients received VKAs according to a written protocol, whereas physician monitoring was
performed according to individual practice. An independent analysis of ED visits and hospitalizations due to complica-
tions of anticoagulation in patients receiving long-term VKAs between July 1, 2008, and December 31, 2008, was
performed. The average cost of ED visits and hospitalizations was calculated for each patient cohort. The expense of each
was amortized for a 12-month period to determine the annual cost of anticoagulation morbidity per 100 patients treated.
Results: Long-term VKAs were used to treat 2397 patients. Physicians managed 2266 patients (95%; group I) and the AS
monitored 131 patients (5%; group II). In group I, 247 patients (10.9%) visited the ED, with an average cost of $288 per
visit; the ED cost per patient treated was $31. In group II, two patients (1.5%) visited the ED, with an average cost of
$139 per patient. The ED cost per patient treated was $2, leading to annual savings of $5800 per 100 patients (P 
.0006). Complications of anticoagulation required hospitalization in 289 group I patients (12.8%), with an average cost
of $15,125 per hospitalization and $1929 per patient treated and in three group II patients (2.3%), with an average cost
of $17,794 per hospitalization and an average cost of $401 per patient treated. When the savings from ED visits and
hospitalizations were combined, AS-managed anticoagulation led to annual savings of $305,600 (P  .0004). Subtract-
ing the cost of staff services resulted in a yearly net savings of $241,400 per 100 patients (P< .0001) managed by the AS.
Conclusions: Management of long-term VKA therapy by an AS using established protocols appears to reduce anticoag-
ulationmorbidity and results in significant cost savings by reducing the number of ED visits and hospitalizations. ( J Vasc
Surg 2011;54:1404-7.)
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bVitamin K antagonists (VKAs) are the mainstay of
anticoagulation for venous and cardiogenic thromboem-
bolic disease.1 Long-term anticoagulation with VKAs
prevents stroke and death in patients with atrial fibrilla-
tion2 and prevents death and recurrence in patients with
venous thromboembolism.3 However, warfarin com-
pounds require careful dose monitoring to maintain a
level of anticoagulation in a therapeutic range. Suprath-
erapeutic levels increase bleeding risks and subtherapeu-
tic anticoagulation increases the risk of thromboembolic
complications. The U.S. Food and Drug Administration
(FDA) found that anticoagulants were the most com-
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1404on pharmaceutical agents associated with complica-
ions.4 Moreover, warfarin was among the top 10 med-
cations with serious complications, and in 2003 and
004, it was the pharmaceutical agent whose complica-
ions most commonly resulted in death.4 It is therefore
rucial to carefully monitor patients receiving oral anti-
oagulation therapy.
Long-term warfarin therapy can be managed by the
hysician or an organized anticoagulation service (AS).
ecause of the recognized complications of inadequate or
xcessive anticoagulation and the recognized benefits of an
stablished protocol-driven AS,5-7 The Toledo Hospi-
al and Jobst Vascular Institute organized a dedicated
S directed by a physician and managed by a nurse-
ractitioner and registered nurse. Paramount Health Care,
he health insurance provider for ProMedicaHealth System
which includes The Toledo Hospital), independently an-
lyzed the complications of anticoagulation resulting in
mergency department (ED) visits and hospitalizations,
ypothesizing that an AS would provide more cost-
ffective care than routine physician monitoring of antico-
gulation. Specifically, the cost of complications generated
y these two measures could be objectively assessed and
ssigned to patients treated by routine physician care or the
w
w
a
i
a
t
o
p
T
t
o
s
b
d
g
e
t
R
w
(
A
i
a
p
(
a
c
m
t
t
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 5 Aziz et al 1405AS. In this article we report the largest study of patients
managed with long-term VKAs by routine physician care or
an AS, using costs of ED visits and hospitalizations as
objective end points for analysis reported by the insurance
carrier of the patients.
METHODS
All patients receiving VKAs for long-term anticoagula-
tion who were covered by Paramount Health Care insur-
ance between July 1, 2008 and December 31, 2008 form
the basis of this study. Patients underwent routine blood
testing of warfarin effect using the international normalized
ratio (INR), and their warfarin dose was adjusted according
to their INR. Point-of-care testing was not used. Compli-
cations of anticoagulation were defined as those requiring
ED visits and hospitalization and had International Classi-
fication of Diseases, 9th Edition codes for thrombosis or
hemorrhage. Costs for each were recorded. After approval
from the Institutional Review Board, patient data were
retrieved using the Paramount database. Specific out-
come measures were the numbers and costs of ED visits
and hospitalizations resulting from complications of
anticoagulation.
Patients were divided into two groups according to the
management of their anticoagulation: group I included
patients who were managed by physicians (all physicians
managing long-term anticoagulation in their patients) and
group II comprised patients managed by the AS. Patients
managed by the AS were those referred by cardiologists
(atrial fibrillation, prosthetic valves), vascular surgeons
(acute arterial and venous thrombotic disorders), internists,
oncologists, orthopedists, primary care, neurologists, and,
to a lesser degree, other specialists.
The costs of ED visits and hospitalization were docu-
Table I. Cost of monitoring vitamin K therapy by physicia
Variables Group I
Patients, No. (%) 2266 (94.5)
ED visits
Patients (%) 247 (10.9)
Cost, $
Per ED visit 288
Per patient/6 mon 31
Savings
Per patient/6 mon
Per patient/year
Per 100 patients/year
Hospitalizations
Patients, No. (%) 289 (12.8)
Cost, $
Per hospitalization 15,125
Per patient/6 mon 1929
Savings
Per patient/6 mon
Per patient/year
Per 100 patients/year
Annual savings per 100
patients treated by AS
AS, Anticoagulation service; ED, emergency department.mented for each patient, and the average cost per patient eas calculated for each patient cohort. The expense of each
as amortized for a 12-month period to determine the
nnual cost of anticoagulation morbidity by each monitor-
ng method. When costs per patient were calculated,
mounts were rounded to the nearest dollar.
Statistical methods. The generic cost per ED visit was
he same for all, with modest differences due to the number
f diagnostic tests; therefore, the group-wise average cost
er patient was governed by its incidence of ED visits.
hus, the comparison of average costs was converted into
he comparison of incidences. Owing to the sparse feature
f the data (2266 vs 131), the Mantel-Haenszel 2 test was
elected to make an inference on the odds ratio, which
ridges the assessment on incidences and adjusts the sample
isparity. The same method was applied to analyze the two
roups for the effect on hospital costs per patient and the
ffect on the combination costs of the ER visit and hospi-
alization. A value of P  .05 was considered significant.
ESULTS
During the 6-month study, 2397 patients were treated
ith VKAs (Table I), which was managed in 2266 patients
94.5%) by physicians (group I) and in 131 (5.5%) by the
S (group II).
ED costs. Complications of anticoagulation resulted
n 247 patients (10.9%) in group I seeking the ED. The
verage cost per ED visit was $288 and the cost of ED visits
er patient treated was $31. In the group II cohort, two
1.5%) required ED visits due to complications of antico-
gulation, with an average cost per ER visit of $139 and
ost per patient treated of $2 (P  .02). Anticoagulation
anagement by the AS resulted in a $29 savings per patient
reated per 6 months, or an annualized savings per patient
reated of $58. Therefore, the annualized reduction in ED
roup I) vs by an anticoagulation service (group II)
Group II Total, $ P
131 (5.5) 2397
2 (1.5) 249
139
2
29
58
5800 .0006
3 (2.3) 15.1
17,794
401
1528
3056
305,600 .0004
311,400n (gxpense per 100 patients was $5800 (P  .0006).
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November 20111406 Aziz et alHospitalization costs. Complications of anticoagula-
tion resulted in hospital admission for 289 patients (12.8%)
in group I and for three patients (2.3%) in group II. The
average cost of hospitalization was $15,125 in group I and
$17,794 in group II, and the cost per patient treated over 6
months was $1929 in group I and $401 in group II.
Anticoagulation management by the AS led to a savings of
$1528 per patient over 6 months. Annualized per-patient
reduction in hospitalization expenses as a result of manage-
ment by the AS was $3,056, or $305,600 per 100 patients
(P  .0004).
Cost of staff services. The actual cost of staffing the
AS (physician time not included) for the 6-month period
was $98,952. Of the 283 patients who were managed by
the AS during this period, 152 patients had different health
insurance carriers and were not included in this analysis.
The cost of staff services per patient treated for 6 months
was $350. The cost of staff services for 100 patients over 6
months was $35,000; hence, the annualized expense of
staff required to treat 100 patients was $70,000.
Net savings. Subtracting the expense of staff services
from the overall cost of complications yields the sav-
ings associated with the AS (Table I). The annualized
savings for 100 patients for ED visits and hospitalizations
was $311,400. Subtracting the cost of personnel from total
savings led to net savings of $241,400 per year per 100
patients (P  .0001).
DISCUSSION
Proper dosing of warfarin is crucial to avoid subthera-
peutic or supratherapeutic anticoagulation. Observations
from this study suggest that patients whose anticoagulation
is managed by an AS require less frequent visits to the ER
and fewer hospitalizations due to complications of antico-
agulation. The reason for the benefit of the AS is key.
Although data were not available regarding the frequency
of INR testing or the frequency of patient contact, our
strong impression is that patients managed by the AS had
more frequent blood tests and patient contact. This impres-
sion is from first-hand observation of anticoagulation in
physician practices and discussions with others on how
anticoagulation is managed. If blood tests were not per-
formed as scheduled by the AS, patients were promptly
contacted and follow-up was completed. As a result, the
health system saves more money when an AS manages
anticoagulation; however, the cost of laboratory studies
would be marginally higher. We believe that long-term
anticoagulation patients who are monitored by an AS re-
ceive better and more cost-effective care.
The cost savings per patient on anticoagulation treated
was a substantial $1714 per year after subtracting the actual
cost of the staff of the AS. However, the AS was capable of
handling more than the 283 patients at the time of the
study. A more representative patient load is 400 with the
same personnel, which would increase the savings per pa-
tient to $1919. Additional savings would be realized with
economy of scale and improved information technology. fVKAs have been the mainstay of long-term anticoagu-
ation therapy for 50 years.2 They have been used to
chieve anticoagulation for patients with prosthetic heart
alves, atrial fibrillation, venous thromboembolism, and
ascular grafts, and in patients with myocardial infarction.
t is crucial to achieve the optimal level of anticoagulation
ecause the risk of thrombosis or embolism is high with
ubtherapeutic INRs, and the risk of hemorrhagic compli-
ations rapidly accelerates as the INR exceeds 4.8,9 It is
hallenging to use VKAs in clinical practice because of
everal factors:
. therapeutic levels can be difficult to achieve;
. dosing is not standardized, although guidelines are
available;
. excessive anticoagulation can lead to bleeding compli-
cations, whereas under anticoagulation leads to throm-
botic complications; and
. they interact with other drugs and diet.
Retrospective studies have shown that the incidence of
ajor bleeding can be as high as 10% at 24 months, and the
ncidence of thromboembolic events can be as high as 13%
t 24 months among patients whose anticoagulation is
anaged by physicians.10 Generally, if anticoagulation is
anaged by an AS, patients are less likely to sustain a
emorrhagic complication or thromboembolic phenome-
on. Several studies have shown that the incidence of major
leeding drops between 1.4%11 and 4.3%.12,13 Fihn et al14
onducted a retrospective review of patients receiving
KAs at five different ASs and found that the incidence of
ajor bleeding was 2% at 3 years. Possible explanations for
his difference include the organized protocol-driven care,
ore frequent INR checks, and implementation of self-
mprovement programs by the AS.
Chiquiette et al5 retrospectively studied 145 patients
hose anticoagulation was managed as usual medical care
nd 183 whose anticoagulation was managed by an AS.
he incidence of major bleeding per patient-year was 3.9%
nd 1.6% in the two groups, respectively. Chamberlain et
l6 performed a retrospective review of 779 patients whose
nticoagulation was managed by physicians and 446 pa-
ients whose anticoagulation was managed by an AS. The
D visit rate resulting from complications of anticoagula-
ion per 100 patient-years was 14.8 and 9.5 for the two
roups, respectively.
The limitations of our study are that it is retrospective
nd neither prothrombin times nor INR values at the time
f ED visits or hospital admissions were available. More-
ver, we had no data on initiation or discontinuation of
nticoagulation during the study period, and patient mor-
ality and demographic data are not available.
However, the strength of this study is that it is the result
f an independent analysis of a computerized database by a
ealth insurer to determine if an AS was cost-effective. The
atient claims are reliable, because expenditure information
rom health insurance companies is generally accurate.
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The high costs of treating complications or failure of
anticoagulation can be avoided if anticoagulation is moni-
tored by a dedicated AS. Several other authors have found
similar cost savings in AS-managed care (Table II). Gray et
al7 showed that the treatment by an AS was successful in
preventing hospitalizations resulting from hemorrhage or
thromboembolism. Patients were hospitalized for 3.22
days per patient treatment-year in the control group vs
0.048 days per patient treatment year in the AS group. The
net savings in reduced hospitalization costs per year in the
treatment group was $211,776. Similarly, Chiquette et al5
showed that monitoring patients by an AS reduced annual
health care costs by $132,086 per hundred patients.
This study is the largest to date reporting a cost analysis
of an AS and reinforces the findings of prior reports. It
provides insight into the economic benefit of proper main-
tenance of anticoagulation. We have shown that patients
who were managed by the AS had less frequent ED visits
and fewer hospitalizations, thus being more cost-effective
when compared with traditional physician-managed anti-
coagulation. As a result of these observations, plans are
underway to extend AS monitoring to a larger percentage
of patients requiring long-term anticoagulation. Most
large health insurers cover thousands of patients who re-
ceive long-term anticoagulation with warfarin. The magni-
tude of savings offered by an AS can be equaled by few
other cost-saving initiatives while at the same time substan-
tially improving patient care.
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